Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABEO

Abeona Therapeutics Inc.

Healthcare | Biotechnology

No licensed closing price on file for ABEO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$1.01

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 10:11 UTC.

What Abeona Therapeutics Inc. does

Abeona Therapeutics is a biopharmaceutical company that develops cell and gene therapies for rare genetic diseases. The FDA approved ZEVASKYN, an autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease caused by a defect in the COL7A1 gene. ZEVASKYN is manufactured at the company's facility in Cleveland, Ohio and administered through a network of qualified treatment centers.

Summarized from Abeona Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (FY2025)$1.01
Return on equity44.71%
Debt/equity0.12

Revenue, margins & earnings

FY2021: net loss $85M on revenue $3M$3MFY2021FY2022: net loss $40M on revenue $1M$1MFY2022FY2023: net loss $54M on revenue $4M$4MFY2023FY2025 Revenue: $6M — margin split not shown (non-operating gains)FY2025: net income $71M exceeded revenue $6M by $65M — non-operating gains (e.g. asset sales), not operating profit$6MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-29
  • 2026-09-29Chief Executive OfficerSale-19,608$101.1K
  • 2026-09-29Chief Commercial OfficerSale-4,902$25.3K
  • 2026-09-29SVP, Chief Legal OfficerSale-6,727$34.7K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Abeona Therapeutics Inc. do?

Abeona Therapeutics is a biopharmaceutical company that develops cell and gene therapies for rare genetic diseases.

When did ABEO last file with the SEC?

Abeona Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 10:11 UTC. This page is also available as JSON at /api/data?ticker=ABEO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABEO and 5,000+ tickers.

Create a free account — keep ABEO
For your agent
GET /api/data?ticker=ABEO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt